APOE4 genotype is reshaping eligibility, dosing, and disclosure
Anti-amyloid trial readouts and post-marketing surveillance both show APOE4 homozygotes face higher ARIA risk — pushing genotype testing into pre-treatment workflows.
A genetic test is moving from research curiosity to a near-mandatory step before disease-modifying therapy.
APOE4 is the strongest common genetic risk factor for late-onset Alzheimer's. It is also a strong modifier of ARIA risk: homozygotes show meaningfully higher rates of imaging abnormalities — and of symptomatic ARIA — than non-carriers across both lecanemab and donanemab populations.
The clinical consequence is that APOE genotyping is now de facto part of the pre-treatment workup at most centers prescribing anti-amyloid therapy. That raises issues the field has not fully resolved:
- Disclosure. APOE4 carries implications beyond the immediate treatment decision, including for relatives.
- Eligibility variation. Some health systems have moved to restrict therapy in homozygotes; others continue with intensified monitoring.
- Counselling capacity. Genetic counselling is in short supply, and most prescribers are not trained to deliver it.
Genotype-stratified treatment is a familiar concept in oncology. Its arrival in dementia care is new — and the supporting infrastructure is still catching up.
Key sources
- FDA prescribing information — Leqembi (lecanemab) APOE4 subgroup labelling
- FDA prescribing information — Kisunla (donanemab) APOE4 subgroup labelling
- CLARITY-AD and TRAILBLAZER-ALZ 2 APOE4 subgroup analyses